蘋果、Alphabet及英偉達等擬斥7.35億美元買入Arm股份
軟旗集團旗下晶片設計公司Arm周二(5日)啟動IPO路演,蘋果(AAPL.US)、Alphabet(GOOGL.US)、英偉達(NVDA.US)、英特爾(INTC.US)、三星及台積電(TSM.US)等科技公司有興趣購買高達7.35億美元的Arm股票。
Arm將發售9,550萬美國存託證券,發行價介乎47至51美元,集資額最高達48.7億美元,公司估值或達520億美元。
於2020年英偉達宣布計劃以400億美元收購Arm,但交易遭到美國及英國監管機構反對。英偉達行政總裁黃仁勳在Arm路演中表示,Arm是一間非凡的公司,公司正與Arm合作開發新的雲數據中心生態系統。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.